Liposarcomas of the paratesticular tissue is a rare pathological entity. The symptoms are similar to inguinal hernias or hydroceles. We present the case of an 84-year-old man with a rare paratesticular liposarcoma that manifested as painless right hemiscrotal swelling. Testicular tumour markers were negative. Imaging revealed a heterogeneous mass with a fat component. He underwent a radical orchiectomy on the left side to remove the associated mass. This revealed dedifferentiated liposarcoma (DDLS) with rhabdomyoblastic differentiation and MDM2 amplification. The surgical margins were negative, and the patient had a metastatic workup that included magnetic resonance imaging (MRI) of the abdomen and pelvis. Because of the disease's rarity, there is no clear agreement on radiotherapy and chemotherapy roles.

Download full-text PDF

Source
http://dx.doi.org/10.14712/23362936.2023.35DOI Listing

Publication Analysis

Top Keywords

dedifferentiated liposarcoma
8
rhabdomyoblastic differentiation
8
paratesticular dedifferentiated
4
liposarcoma rhabdomyoblastic
4
differentiation case
4
case report
4
report review
4
review literature
4
literature liposarcomas
4
liposarcomas paratesticular
4

Similar Publications

Pericardial and cardiac masses in patients with established malignant neoplasms represent a diagnostic and therapeutic challenge. We present the case of a 66-year-old woman with history of myxoid liposarcoma of the left thigh who had an unexpected recurrence in the pericardium 12 years later.

View Article and Find Full Text PDF

Background: Anlotinib has demonstrated durable clinical benefits in patients with unresectable or metastatic bone and soft-tissue sarcomas.

Methods: 92 patients treated with chemotherapy combined with or without anlotinib were collected and analyzed. The objective response rate (ORR) and disease control rate (DCR) were analyzed.

View Article and Find Full Text PDF

A subgroup analysis of a randomized study demonstrated that patients with advanced or metastatic liposarcoma treated with eribulin had longer overall survival and progression-free survival compared to those treated with dacarbazine, suggesting eribulin as a therapeutic option for advanced liposarcoma. Therefore, this study aims to evaluate the cost-effectiveness of eribulin versus dacarbazine in the treatment of advanced liposarcoma. We established a 10-year Markov model to compare the cost-effectiveness of eribulin and dacarbazine regimens.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!